GLP-1 receptor agonist
An earlier-generation GLP-1 receptor agonist used in diabetes and weight-management contexts.
A well-studied, earlier-generation GLP-1 medicine with trial support for its registered indications. Newer agents have generally shown larger effects in weight studies.
Gastrointestinal side effects are common; it is a daily injection. Use is overseen by a prescriber who manages contraindications.
A registered prescription medicine in Australia under defined brand names. Supply is via prescription and dispensing pharmacy.
Lawful access is via prescription and pharmacy dispensing of the registered product.
This entry is general information about Liraglutide, not a recommendation to use it. We don’t provide dosing, protocols or sourcing. Speak to a registered practitioner.
This is general education, not medical advice. Peptides.au does not sell, supply, recommend or promote any product or clinic. Always speak with a registered Australian health practitioner before making any health decision.